Maze tumbles despite positive data for kidney disease drug

Investors had reservations about data for a drug that could compete with a candidate from Vertex in APOL1-mediated kidney disease.

By Delilah Alvarado • March 25, 2026

Beam posts positive data on base editing treatment for AATD

Updated data showed the biotech's approach to the rare lung and liver condition helped restore functional protective proteins in a small study.

By Gwendolyn Wu • March 25, 2026

Explore the Trendline➔

Emerging biotech

New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

By BioPharma Dive staff

Sarepta sees early success with RNAi drugs from Arrowhead

Long-awaited results from Phase 1/2 studies lifted Sarepta’s stock and, according to the company, suggest potential for two medicines to treat muscle-weakening conditions.

By Kristin Jensen • March 25, 2026

RA Capital targets China with latest SPAC deal

The prominent investor aims to merge its latest special purpose acquisition company with a Chinese biotech, according to a securities filing.

By Gwendolyn Wu • March 24, 2026

Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases

Acquiring Ouro Medicines, which launched last year, hands Gilead an antibody designed to bind to BCMA and CD3, a pair of immune cell proteins that are popular targets for drugmakers.

By Gwendolyn Wu • March 24, 2026

Immutrin raises $87M to advance drug for progressive heart disease

The fresh funding will help the biotech startup advance a candidate to treat a genetic disorder, “ATTR-CM,” that has become a battleground for companies like Pfizer, Alnylam and BridgeBio.

By Delilah Alvarado • March 24, 2026

Karyopharm myeloma drug yields mixed data in myelofibrosis trial

Xpovio combined with Incyte’s Jakafi helped on one key measure but missed on other goal in a disorder that, by one analyst’s estimates, could triple the company’s revenue.

By Jonathan Gardner • March 24, 2026

How former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup

Cohen says he looked at around two dozen companies since Acorda wound down. Oryon Cell Therapies, with its funding, data and “autologous” approach, stood out amongst the crowd.

By Jacob Bell • March 24, 2026

Apogee strengthens case for longer-lasting eczema drug

Company shares climbed by more than 20% on Phase 2 study results suggesting the therapy could provide sustained relief when administered once every three or six months.

By Jonathan Gardner • March 23, 2026

FDA seeks feedback on voucher program; Study data lift ‘overhang’ on Insmed shares

Industry executives can share their views on the “national priority” program at a June meeting. Elsewhere, Sanofi licensed a T cell engager and Acorda’s former CEO resurfaced at a cell therapy startup.

By Ben Fidler • March 23, 2026

Earendil Labs, an AI-powered drugmaker, hauls in $787M

The hefty funding will support a U.S.- and China-based startup that’s amassed a pipeline of nearly 20 drugs and formed two lucrative partnerships with Sanofi. 

By Ben Fidler • March 20, 2026

Rhythm obesity drug wins broader use from FDA

Imcivree’s approval in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to be worth more than $1 billion.

By Ben Fidler • March 20, 2026

A biotech VC sees early signs of a turnaround for startups

After a lengthy downturn, renewed optimism is building among young drugmakers and their backers as a new funding wave takes shape, said Santé Ventures’ Omar Khalil.

By Michael Gibney • March 19, 2026

Aspen’s fresh Parkinson’s data; Aldeyra tanks following FDA rejection

Aspen Neuroscience presented positive Phase 1/2 data for its stem cell-derived therapy. Elsewhere, Aldeyra lost over half its market value following a rejection from the FDA.

By BioPharma Dive staff • March 18, 2026

Crossbow raises $77M for new cancer immunotherapies

Backed by more than a dozen investors, the biotech startup will use the funding to further a Phase 1 trial of its lead program CBX-250.

By Gwendolyn Wu • March 18, 2026

Chinese biotech startup Excalipoint banks $69M for next-gen T cell engagers

The funding, which ranks as one of the largest of its kind for a China-based drug startup, will support a portfolio of multifaceted antibodies the company believes to be advances over existing treatments.

By Gwendolyn Wu • March 18, 2026

Bicycle to lay off 30% of staff, pivot away from Padcev challenger

The company now expects a longer path to approval than anticipated, leading it to deprioritize a therapy billed as a threat to Pfizer’s fast-selling bladder cancer drug. 

By Jonathan Gardner • March 17, 2026

R1 starts up with $78M, aiming for a better kidney drug

The startup believes a pill it licensed from a Chinese biotech company could be more potent, and convenient to take, than existing treatments for a common complication of chronic kidney disease.

By Gwendolyn Wu • March 17, 2026

CytomX surges on positive data for ‘masked’ ADC in colorectal cancer

Company shares spiked more than 60% after the therapy surpassed Wall Street benchmarks in Phase 1 testing against late-line colorectal tumors. 

By Delilah Alvarado • March 16, 2026

Structure’s GLP-1 pill shows ‘best-in-class’ potential in obesity trial

Testing revealed weight loss effects some Wall Street analysts believe compare favorably to Lilly’s orforglipron, which regulators could approve within weeks. 

By Jonathan Gardner • March 16, 2026

Sarepta tests new Elevidys safeguards; Sana advances diabetes cell therapy

Sarepta has begun evaluating a regimen meant to lower the risk of liver damage in Elevidys recipients. Elsewhere, Inovio laid off staff and a Bayer kidney drug notched another trial victory.

By Ben Fidler • March 16, 2026

With FDA go ahead, a China biotech notches a first in cell therapy testing

The trial clearance for Shanghai-based Unixell is another step forward for the rapidly advancing Chinese biotech ecosystem, which has invested heavily in cell and gene therapy technology.

By Jacob Bell • March 13, 2026

Evotec, Vistagen lay off staff; Immutep shares collapse on study failure

Evotec will cut 800 employees in its second layoff round since 2024. Elsewhere, Ultragenyx got a needed win and a twice-rejected cell therapy is getting an audience at the FDA.

By BioPharma Dive staff • March 13, 2026

FDA to unify agency’s ‘fragmented’ safety surveillance system

Combining the disparate databases used to detect potential issues with drugs, vaccines and other products into a single dashboard will enhance their utility and cut costs, the agency said.

By Kristin Jensen • March 12, 2026

Biogen builds case for Spinraza successor with fresh data

More early-stage data show the drug, called salanersen, appeared to have positive effects on neurodegeneration and motor function in patients previously treated with Novartis' Zolgensma.

By Gwendolyn Wu • March 11, 2026